-
-
-
-
-
-
-
Acadia Pharma (ACAD) Appoints Catherine Owen Adams as New CEO
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrom
-
-
-
-
-
-
-
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
-
-
-
-
-
-
-
Acadia Pharma (ACAD) Tops Q4 EPS by 5c
-
-
-
-
-
-
-
Pre-Open Movers 08/06: (SEAS) (VTL) (CTWS) Higher; (OVID) (BID) (PX) Lower (more...)
-
1,167,109 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

